- Home
- CATX vs XOMA Comparison
CATX vs XOMA Comparison
Compare CATX & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | XOMA |
|---|---|---|
| Founded | 1983 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.9M | 471.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CATX | XOMA |
|---|---|---|
| Price | $3.03 | $42.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $12.11 | ★ $52.50 |
| AVG Volume (30 Days) | ★ 1.3M | 97.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $22.29 |
| 52 Week High | $6.16 | $42.81 |
Technical Indicators
Market Signals| Indicator | CATX | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 28.04 | 66.32 |
| Support Level | $1.98 | $37.00 |
| Resistance Level | $3.80 | $42.81 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | -0.07 | -0.20 |
| Stochastic Oscillator | 0.38 | 75.25 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.